Search | IOVS | ARVO Journals

Showing 1 – 20 of 20

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2022

Preclinical pharmacology and safety of GT005, an investigational gene therapy targeting the complement pathway for the treatment of Geographic Atrophy

Julian Esteve-Rudd; James Francis; Jane Hughes; Scott Ellis

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):294 – F0097.

ARVO Annual Meeting Abstract June 2022

In vivo expression and efficacy following subretinal delivery of GT005, an investigational gene therapy for the treatment of geographic atrophy (GA)

Dimitrios Stampoulis; Josephine Joel; Anna Dreismann; Emanuela Gardenal; Jane Hughes; Scott Ellis; Julian Esteve-Rudd

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):293 – F0096.

ARVO Annual Meeting Abstract June 2020

GT005, a gene therapy for the treatment of dry age-related macular degeneration (AMD)

Scott Ellis; Anna Buchberger; Julie Holder; elise Orhan; Jane Hughes

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):2295.

ARVO Annual Meeting Abstract June 2020

Proteomic analysis of vitreous humor samples obtained from donors with and without age-related macular degeneration (AMD) reveal an overactivation of complement protein expression.

Anna Buchberger; James Francis; Ashley Frazer-Abel; Selina McHarg; Paul N Bishop; Scott Ellis; Jane Hughes

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):3650.

ARVO Annual Meeting Abstract June 2017

Evaluation of integrase-deficient vectors for lentiviral gene-transfer in corneal endothelium

Daniel Thieme; Scott Ellis; Thomas Armin Fuchsluger; Friedrich E Kruse

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):4085.

ARVO Annual Meeting Abstract September 2016

Phase I Safety and Tolerability results for RetinoStat ® , a Lentiviral Vector Expressing Endostatin and Angiostatin, in Patients with Advanced Neovascular Age-Related Macular Degeneration

Andreas K Lauer; Peter A Campochiaro; Elliott H Sohn; Michelle Kelleher; Richard Harrop; Julie Loader; Scott Ellis; Kyriacos Mitrophanous

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12)

ARVO Annual Meeting Abstract June 2015

EncorStat ® : a human donor cornea genetically engineered to resist rejection in high risk patients

Scott Ellis; Maria Parker; Vicky Kennedy; Laura McCloskey; Trevor McFarland; Matt Hartzell; Binoy Appukuttan; Tim Stout; Kyriacos Mitrophanous

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):2262.

ARVO Annual Meeting Abstract June 2015

Results from the Phase I GEM study, evaluating safety and tolerability of subretinally-injected lentiviral vector (RetinoStat ® ) for the treatment of wet age-related macular degeneration (AMD)

Simon Chandler; Peter Campochiaro; Andreas Lauer; Elliott H Sohn; Tim Stout; Michelle Kelleher; Richard Harrop; Scott Ellis; Kyriacos Mitrophanous

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):2284.

ARVO Annual Meeting Abstract April 2014

NONCLINICAL DEVELOPMENT OF ENCORSTAT®, DONOR CORNEAL TISSUE GENETICALLY ENGINEERED TO PREVENT GRAFT REJECTION

Scott Ellis; Kyriacos Mitrophanous; Maria A Parker; Vicky Scripps; Trevor J McFarland; Matthew Hartzell; Binoy Appukuttan; Tim Stout

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):3235.

ARVO Annual Meeting Abstract April 2014

Lentiviral Gene therapies for wet AMD, Stargardt macula dystrophy and Usher Syndrome 1B : clinical trial updates

Madhu Davies; Scott Ellis; Nicola Adams; Katie Binley; Michelle Kelleher; Kyriacos Mitrophanous

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):3299.

ARVO Annual Meeting Abstract June 2013

Glaucoma-GT, a novel gene therapy treatment for primary open-angle glaucoma

Scott Ellis; Katie Binley; Vicky Scripps; Sharifah Iqball; Stuart Naylor; Kyriacos Mitrophanous

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):2741.

ARVO Annual Meeting Abstract June 2013

The LentiVector ® Gene Therapy Platform for Ocular Disease: a clinical update

Kyriacos Mitrophanous; Scott Ellis; James Miskin; Katie Binley; Michelle Kelleher; Cherry Lucas; Stuart Naylor

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):2744.

ARVO Annual Meeting Abstract June 2013

Comparison of Neovascularization, Opacification and Cornea thickness in a Rabbit Model of Keratoplasty with Interrupted or Continuous Suture Techniques by Cornea fluorescein angiography and corneal OCT

Maria Parker; Trevor McFarland; Winston Chamberlain; Scott Ellis; Kyriacos Mitrophanous; Tim Stout

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):3071.

Retina June 2013

Transduction of Photoreceptors With Equine Infectious Anemia Virus Lentiviral Vectors: Safety and Biodistribution of StarGen for Stargardt Disease

PDF

Katie Binley; Peter Widdowson; Julie Loader; Michelle Kelleher; Sharifah Iqball; Georgina Ferrige; Jackie de Belin; Marie Carlucci; Diana Angell-Manning; Felicity Hurst; Scott Ellis; James Miskin; Alcides Fernandes; Paul Wong; Rando Allikmets; Christopher Bergstrom; Thomas Aaberg; Jiong Yan; Jian Kong; Peter Gouras; Annick Prefontaine; Mark Vezina; Martin Bussieres; Stuart Naylor; Kyriacos A. Mitrophanous
TAGS: disease vectors, equine infectious anemia virus, eye, gene transfer techniques, lentiviral vector, macaca, oryctolagus cuniculus, photoreceptors, safety, spatial vectors
Invest. Ophthalmol. Vis. Sci.. 2013; 54(6):4061-4071. https://doi.org/10.1167/iovs.13-11871

ARVO Annual Meeting Abstract March 2012

LentiVector® Platform, a Highly Effective Equine Infectious Anaemia Virus-based Lentiviral Gene Therapy Platform for Ocular Disease

Scott Ellis; James Miskin; Katie Binley; Jackie de Belin; Julie Loader; Michelle Kelleher; Stuart Naylor; Kyriacos Mitrophanous

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):1912.

ARVO Annual Meeting Abstract March 2012

Evaluation Of EIAV Lentiviral Vectors In A Rabbit Model Of Corneal Rejection

Maria A. Parker; Trevor McFarland; Binoy Appukuttan; Matt Harzell; Kyriacos Mitrophanous; Tim Stout; Scott Ellis

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):2397.

ARVO Annual Meeting Abstract April 2011

Efficacy, Safety And Tolerability Of StargenTM, A Lentiviral-vector Based Gene Therapy For The Treatment Of Stargardt Disease, In Rabbits And Macaques

Peter Widdowson; Scott Ellis; Katie Binley; Martin Bussières; Annick Prefontaine; Mark Vezina; Rando Allikmets; Jian Kong; Kyriacos Mitrophanous; Stuart Naylor

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):479.

ARVO Annual Meeting Abstract April 2011

Biodistribution and Immunological Responses to the Lentiviral-Vector Based Gene Therapy Product RetinoStat® Following Subretinal Injection in Rabbits and Rhesus Macaques

Stuart M. Naylor; Michelle Kelleher; Julie Loader; Jackie de Belin; James Miskin; Georgina Ferrige; Marie Carlucci; Margaret Esapa; Scott Ellis; Peter Widdowson

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):484.

ARVO Annual Meeting Abstract April 2011

Safety And Tolerability Of Retinostat®, A Lentiviral-vector Based Gene Therapy Product For The Treatment Of Wet Age-related Macular Degeneration, In Rabbits And Monkeys

Scott Ellis; Peter Widdowson; Katie Binley; T. Michael Nork; Paul Miller; Vlad Bantseev; Brian Christian; Kyriacos Mitrophanous; Stuart Naylor

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):488.

ARVO Annual Meeting Abstract April 2011

Subretinal Delivery Of Eiav-based Lentiviral Vectors In The Shaker1 Mouse Model For Usher Syndrometype 1b : Development Of Ushstat®

Marisa L. Zallocchi; Katie Binely; Yatish Lad; Scott Ellis; Peter Widdowson; Kyri Mitrophanous; You-Wei Peng; Linda Cheung; Dominic Cosgrove

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):489.

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

Preclinical pharmacology and safety of GT005, an investigational gene therapy targeting the complement pathway for the treatment of Geographic Atrophy

In vivo expression and efficacy following subretinal delivery of GT005, an investigational gene therapy for the treatment of geographic atrophy (GA)

GT005, a gene therapy for the treatment of dry age-related macular degeneration (AMD)

Proteomic analysis of vitreous humor samples obtained from donors with and without age-related macular degeneration (AMD) reveal an overactivation of complement protein expression.

Evaluation of integrase-deficient vectors for lentiviral gene-transfer in corneal endothelium

Phase I Safety and Tolerability results for RetinoStat ® , a Lentiviral Vector Expressing Endostatin and Angiostatin, in Patients with Advanced Neovascular Age-Related Macular Degeneration

EncorStat ® : a human donor cornea genetically engineered to resist rejection in high risk patients

Results from the Phase I GEM study, evaluating safety and tolerability of subretinally-injected lentiviral vector (RetinoStat ® ) for the treatment of wet age-related macular degeneration (AMD)

NONCLINICAL DEVELOPMENT OF ENCORSTAT®, DONOR CORNEAL TISSUE GENETICALLY ENGINEERED TO PREVENT GRAFT REJECTION

Lentiviral Gene therapies for wet AMD, Stargardt macula dystrophy and Usher Syndrome 1B : clinical trial updates

Glaucoma-GT, a novel gene therapy treatment for primary open-angle glaucoma

The LentiVector ® Gene Therapy Platform for Ocular Disease: a clinical update

Comparison of Neovascularization, Opacification and Cornea thickness in a Rabbit Model of Keratoplasty with Interrupted or Continuous Suture Techniques by Cornea fluorescein angiography and corneal OCT

Transduction of Photoreceptors With Equine Infectious Anemia Virus Lentiviral Vectors: Safety and Biodistribution of StarGen for Stargardt Disease

LentiVector® Platform, a Highly Effective Equine Infectious Anaemia Virus-based Lentiviral Gene Therapy Platform for Ocular Disease

Evaluation Of EIAV Lentiviral Vectors In A Rabbit Model Of Corneal Rejection

Efficacy, Safety And Tolerability Of StargenTM, A Lentiviral-vector Based Gene Therapy For The Treatment Of Stargardt Disease, In Rabbits And Macaques

Biodistribution and Immunological Responses to the Lentiviral-Vector Based Gene Therapy Product RetinoStat® Following Subretinal Injection in Rabbits and Rhesus Macaques

Safety And Tolerability Of Retinostat®, A Lentiviral-vector Based Gene Therapy Product For The Treatment Of Wet Age-related Macular Degeneration, In Rabbits And Monkeys

Subretinal Delivery Of Eiav-based Lentiviral Vectors In The Shaker1 Mouse Model For Usher Syndrometype 1b : Development Of Ushstat®

To View More...

You must be signed into an individual account to use this feature.